BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 11, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for Dec. 14, 2020

Dec. 14, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3Sbio, ADC, Adelia, Allarity, Alzecure, Anixa, Ascentage, Ashvattha, Brainstorm Cell, Crispr, Cybin, Enzolytics, Eureka, Havn, Hemab, Hummingbird, Immuno-Precise, Intellia, Litevax, Mosaic, Neuraxpharm, Neurorx, Novo Nordisk, Overland, Pharmacyte, Phathom, Reviva, Spectrum, Teon, Unicycive, Verseau, Vivus.
Read More

In the clinic for Dec. 14, 2020

Dec. 14, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aerpio, Amarin, Arvinas, Astrazeneca, Bellus, Biontech, Biophytis, Caladrius, Cytokinetics, Curevac, Daiichi, Freeline, Innovent, Junshi, Kintor, Lilly, Mitsubishi Tanabe, Novartis, Odonate, Pfizer, Polyphor, Poxel, Puma, RDIF, Sanofi, Synlogic, TCR2.
Read More
X-ray scans with highlighted regions

Partners collaborate with Boston Children’s Hospital on ‘explainable’ AI-driven technology

Dec. 11, 2020
By David Godkin
TORONTO – Waterloo, Ontario-based DarwinAI Corp. and Raleigh, N.C.-based Red Hat Inc.are developing a suite of deep neural networks for COVID-19 detection and risk stratification via chest radiography in cooperation with Boston Children’s Hospital. DarwinAI designed COVID-Net as “explainable” artificial intelligence (AI) that illuminates the inner workings of AI-driven medical technologies and promptly offered it on an open-source platform for the broader hospital community.
Read More
Digital illustration of U.S., coronavirus

Harvard’s Mina: Props to HHS’s Giroir for assisting on antigen test development

Dec. 11, 2020
By Mark McCarty
Michael Mina, assistant professor of epidemiology at the Harvard T.H. Chan School of Public Health, again criticized the U.S. FDA for taking a conventional regulatory approach to rapid antigen tests for the pandemic. However, not everyone at the FDA’s parent department deserves brickbats. Mina said Assistant Secretary for Health Brett Giroir deserves a lot of credit for assisting in the effort to stand up pilot studies for rapid antigen tests that could be used to restore the U.S. economy even in the absence of a fully rolled-out vaccination campaign.
Read More

Regulatory actions for Dec. 11, 2020

Dec. 11, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Applied Biocode.
Read More

Other news to note for Dec. 11, 2020

Dec. 11, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akoya Biosciences, Biocogniv, Dermtech, Djo, Litecure, Nanalysis, Nanovibronix, Neovasc, Pear Therapeutics, Roche, Rs2d, Spinal Elements, Ultra Pain Products.
Read More
COVID-19 vaccine vials

Sanofi-GSK delay their COVID-19 vaccine development as Astrazeneca partners with Russia

Dec. 11, 2020
By Lee Landenberger
The Sanofi SA-Glaxosmithkline plc COVID-19 vaccine program is taking a step backward to recalibrate as weak interim phase I/II data showed an insufficient response in patients age 50 and older. The step is a large one, delaying a potential launch until mid-2021 at the earliest and the end of next year at the latest.
Read More
Coronavirus and DNA

New research on COVID-19 genetic variants will guide development of treatments

Dec. 11, 2020
By Nuala Moran
LONDON – A study of genetic variants in patients with life-threatening COVID-19 has shed light on the mechanisms that underpin severe disease, uncovered new drug targets and pointed to approved drugs, including JAK inhibitors and phosphodiesterase type 4 inhibitors, as therapies that could aid recovery.
Read More
Disintegrating coronavirus

CSL, University of Queensland quit COVID-19 vaccine trials due to HIV antibody response

Dec. 11, 2020
By Tamra Sami
PERTH, Australia – The University of Queensland (UQ) and CSL Ltd. are abandoning their trials of an Australian COVID-19 vaccine after recipients generated HIV antibodies during phase I trials. The response means the antibodies produced by the vaccine can interfere with HIV diagnostic tests. However, there was no possibility the vaccine caused infection, and routine follow-up tests confirmed no HIV virus was present, the partners said.
Read More

Regulatory actions for Dec. 11, 2020

Dec. 11, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arix, Biogen, Bristol Myers Squibb, Daiichi Sankyo, Dynavax Technologies, Excellthera, Gilead Sciences, Janssen, Lexicon, Merck, Passage, Sanofi, Seagen, Soleno, V2act, Viiv Healthcare, Xeris.
Read More
Previous 1 2 … 318 319 320 321 322 323 324 325 326 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Art concept for inflammation in the intestines

    Kymera’s IRF5 degrader shows potential in IBD treatment

    BioWorld Science
    At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing